(NASDAQ: CABA) Cabaletta Bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.65%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.68%.
Cabaletta Bio's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast CABA's revenue for 2027 to be $8,325,640,752, with the lowest CABA revenue forecast at $8,325,640,752, and the highest CABA revenue forecast at $8,325,640,752. On average, 2 Wall Street analysts forecast CABA's revenue for 2028 to be $14,133,450,054, with the lowest CABA revenue forecast at $2,286,444,624, and the highest CABA revenue forecast at $25,980,455,484.
In 2029, CABA is forecast to generate $48,199,589,582 in revenue, with the lowest revenue forecast at $48,199,589,582 and the highest revenue forecast at $48,199,589,582.